ClinicalTrials.gg
CompletedNCT03176238EVEREXESUpdated Apr 7, 2020Results posted

Study in Post-menopausal Women With Hormone Receptor Positive, HER2-negative Advanced Breast Cancer

A Phase 3 interventional study of everolimus and exemestane in Post Menopausal Breast Cancer, sponsored by Novartis Pharmaceuticals. Completed at 55 sites in 13 countries. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-04-07.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Registered 4 years 2 months after the study started (first participant enrolled Mar 2013, registered Jun 2017).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
235
Allocation
Not applicable
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 78 studies testing everolimus in Breast Neoplasms — 7 open to participants now, 10 under way, 6 of them phase 3. Everolimus · Breast Neoplasms.

Enrollment
17th of 78
235 · median 55
Started
2013
with 10 others
Phase 3
17 of 78
4 open now
Registered
67th of 78
by date
Lead sponsor
14 of 78
Novartis Pharmaceuticals

Among the 78 studies testing everolimus in Breast Neoplasms, this one is the 17th largest by enrollment, is one of 11 that started in 2013, is one of 17 in phase 3, and was the 67th registered.

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,320 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

7 of the 78 studies testing everolimus in Breast Neoplasms are open now, in 12 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 7 open studies →

About everolimus

Everolimus: first FDA approval 2009 (AFINITOR), first EMA approval 2009. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2,399 Breast Neoplasms studies recruiting now, 1,570 (65%) set no upper age limit and 592 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 78 studies testing everolimus in Breast Neoplasms, or all of them as a file.
02

Study summary

This international, multi-center, open-label, single-arm study evaluated the safety and tolerability profile of everolimus in post-menopausal women with HR positive, HER2 negative locally advanced or metastatic breast cancer after documented recurrence or progression following a non-steroidal aromatase inhibitors (NSAI) therapy in Novartis Oncology emergent growth market (EGM) countries.Data was presented by Asian countries vs Non-Asian countries to confirm no difference in safety and efficacy. Summary statistics were presented.

03

Conditions studied

  • Post Menopausal Breast Cancer

Browse trials for

Keywords

  • post menopausal
  • advanced breast cancer
  • metastatic breast cancer
  • everolimus
  • exemestane
  • mTor inhibitor
  • endocrine therapy
  • human epidermal growth factor
  • estrogen receptor positive
  • adult
  • CRAD001
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • women with , recurrent or locally advanced breast cancer not amenable to curative treatment by surgery or radiotherapy.
  • Histological or cytological confirmation of hormone-receptor positive (HR+) breast cancer.
  • Disease to non-steroidal aromatase inhibitors, defined as:
  • Recurrence while on, or within 12 months (365 days) of completion of therapy with letrozole or anastrozole, or
  • Progression while on, or within one month (30 days) of completion of letrozole or anastrozole treatment for locally advanced or metastatic breast cancer (ABC).
  • Radiological or objective evidence of recurrence or progression on or after the last systemic therapy prior to enrolment.
  • Patients must have had:
  • At least one lesion that could have been accurately measured in at least one dimension

    • 20 mm with conventional imaging techniques or ≥ 10 mm with spiral CT or MRI, or
  • Bone lesions: lytic or mixed (lytic + blastic) in the absence of as defined above.
  • Adequate bone marrow, coagulation, liver and renal function.
  • performance status ≤ 2.

Exclusion criteria

Exclusion Criteria:

  • Patients overexpressing by local laboratory testing (IHC 3+ staining or in situ hybridization positive). Patients with IHC 2+ must have a negative in situ hybridization test.
  • Patients with only non- other than bone (e.g. pleural effusion, ascites).
  • Patients with more than one prior chemotherapy line for ABC. A chemotherapy line is an anticancer regimen(s) that contained at least 1 cytotoxic chemotherapy agent, given for a minimum of 21 days.
  • Previous treatment with mTOR inhibitors.
  • Known to mTOR inhibitors, e.g. Sirolimus (rapamycin).
  • Patients with a known history of seropositivity. Screening for HIV infection at baseline was not required.
  • Patient who were being treated with drugs recognized as being strong inhibitors or inducers of the isoenzyme
  • History of brain or other , including .
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
235 participants (actual)

Study arms

  • Experimental
    everolimus + exemestane

    Everolimus (10 mg) and exemestane (25 mg) tablets taken orally in combination once daily

    Drug: everolimus · Drug: exemestane

Interventions

  • one 10 mg tablet or two 5 mg tablets of everolimus were administered orally once daily on a continuous dosing schedule starting on Day 1

    Also known as: RAD001

  • 25 mg tablet was administered orally once daily on a continuous dosing schedule starting on Day 1

06

What researchers measure

Primary outcomes

  1. Summary of Number of Participants With Treatment Emergent Adverse Events (TEAE) - All Grades

    Adverse events (AEs), serious adverse events (SAEs), changes from baseline in vital signs and laboratory results (hematology, blood chemistry, lipid profile) qualifying and reported as AEs. Although a patient might had two or more adverse events the patient is only counted once in a category. The same patient might appear in different categories. AESI: Adverse events of special interest.

    Time frame: Baseline up to approximately 43 weeks for Asian countires and 32 weeks for Non-Asian countries including a 30 day post treatment follow up period

Secondary outcomes

  1. Percentage of Participants Response Rates (Best Overall and Overall)

    The best overall response for each patient is determined from the sequence of investigator overall lesion responses according to RECIST 1.1: Complete Response (CR)=disappearance of target lesions, Partial Response (PR) was \>=30% decrease in sum of diameter of lesions, Progressive Disease (PD) was \>=20% decrease in sum of diameter of lesions, Stable Disease (SD) does not qualify for PR, CR or PD, Unknown=not documented or assessed. To be assigned a best overall response of CR at least two determinations of CR at least 4 weeks apart before progression are required. To be assigned a best overall response of PR at least two determinations of PR or better at least 4 weeks apart before progression (and not qualifying for a CR) are required. The Overall response rate (ORR) is the percentage of patients with a best overall response of confirmed complete (CR) or partial (PR) response. The 95% confidence intervals (CI) were computed using the Clopper-Pearson method

    Time frame: Baseline up to approximately 43 weeks for Asian countires and 32 weeks for Non-Asian countries

  2. Percentage of Participants Clinical Benefit Rate

    Clinical benefit rate: Patients with best overall response rate of CR (any duration), PR (any duration) and SD with duration of 24 weeks or longer according to RECIST 1.1 criteria: Complete Response (CR)=disappearance of target lesions, Partial Response (PR) was \>=30% decrease in sum of diameter of lesions, Progressive Disease (PD) was \>=20% decrease in sum of diameter of lesions, Stable Disease (SD) does not qualify for PR, CR or PD, Unknown=not documented or assessed. Best overall response of CR = at least two determinations of CR at least 4 weeks apart before progression are required. Best overall response of PR = at least two determinations of PR or better at least 4 weeks apart before progression (and not qualifying for a CR) are required. The Overall response rate (ORR) is the percentage of patients with a best overall response of confirmed complete (CR) or partial (PR) response. The 95% confidence intervals (CI) were computed using the Clopper-Pearson method.

    Time frame: Baseline up to approximately 43 weeks for Asian countires and 32 weeks for Non-Asian countries

  3. Progression Free Survival (PFS)

    PFS is time from date of start of treatment to date of disease progression or death due to any cause, whichever occurs first. b Percentiles with 95% CIs are calculated from PROC LIFETEST output using method of Brookmeyer and Crowley (1982)

    Time frame: Baseline up to approximately 43 weeks for Asian countires and 40 weeks for Non-Asian countries

  4. Percent of Participants Event-free Probability Estimates of Deterioration of Eastern Cooperative Oncology Group (ECOG) Performance Status

    Time to deterioration of ECOG performance status, from baseline will be assessed using the ECOG Performance Status Scale (Oken, 1982). Time to deterioration is the time from date of start of treatment to the date of the event defined as deterioration. Deterioration is defined as an increase in performance status from 0 to 2 or greater, an increase in performance status from 1-2 to 3 or greater, or death due to any cause. Event-free probability estimate is the estimated probability that a patient will remain event-free up to the specified time point. Event-free probability estimates were are obtained from the Kaplan-Meier survival estimates.

    Time frame: Baseline up to approximately 50 weeks

07

Results

Posted Apr 7, 2020

Participant flow

Participant flow — Overall Study
MilestoneAsian Everolimus + ExemestaneNon-Asian Everolimus + Exemestane
Started19936
Completed00
Not completed19936
Withdrew: Unacceptable aes158
Withdrew: Abnormal lab value(s)20
Withdrew: Inter-current illness01
Withdrew: Consent withdrawal142
Withdrew: Lost to follow-up30
Withdrew: Administrative problems10
Withdrew: Death30
Withdrew: Disease progression13322
Withdrew: Tx duration completed per eap01
Withdrew: Patient is switched to commercial drug161
Withdrew: Protocol violation10
Withdrew: Changes in the patient's condition21
Withdrew: Everolimus dose interrupt > 4 wks90

Outcome measures

PrimarySummary of Number of Participants With Treatment Emergent Adverse Events (TEAE) - All Grades

Adverse events (AEs), serious adverse events (SAEs), changes from baseline in vital signs and laboratory results (hematology, blood chemistry, lipid profile) qualifying and reported as AEs. Although a patient might had two or more adverse events the patient is only counted once in a category. The same patient might appear in different categories. AESI: Adverse events of special interest.

Time frame:
Baseline up to approximately 43 weeks for Asian countires and 32 weeks for Non-Asian countries including a 30 day post treatment follow up period
Reported as:
Count of participants · Participants
Summary of Number of Participants With Treatment Emergent Adverse Events (TEAE) - All Grades
ParticipantsAsian Everolimus + ExemestaneNon-Asian Everolimus + ExemestaneTotal
no TEAE404
at least 1 TEAE19536231
at least 1 drug-related TEAE18533218
at least 1 serious TEAE (STEAE)591675
STEAE leading to death6410
Non-fatal STEAE531265
at least 1 drug-related STEAE28836
at least 1 drug-related STEAE - death213
at least 1 drug-related non-fatal STEAE26733
TEAE leading to permanent tx discontinuation251136
1 TE AESI17234206
SecondaryPercentage of Participants Response Rates (Best Overall and Overall)

The best overall response for each patient is determined from the sequence of investigator overall lesion responses according to RECIST 1.1: Complete Response (CR)=disappearance of target lesions, Partial Response (PR) was \>=30% decrease in sum of diameter of lesions, Progressive Disease (PD) was \>=20% decrease in sum of diameter of lesions, Stable Disease (SD) does not qualify for PR, CR or PD, Unknown=not documented or assessed. To be assigned a best overall response of CR at least two determinations of CR at least 4 weeks apart before progression are required. To be assigned a best overall response of PR at least two determinations of PR or better at least 4 weeks apart before progression (and not qualifying for a CR) are required. The Overall response rate (ORR) is the percentage of patients with a best overall response of confirmed complete (CR) or partial (PR) response. The 95% confidence intervals (CI) were computed using the Clopper-Pearson method

Time frame:
Baseline up to approximately 43 weeks for Asian countires and 32 weeks for Non-Asian countries
Reported as:
Number · Percentage of participants
Percentage of Participants Response Rates (Best Overall and Overall)
Percentage of participantsAsian Everolimus + ExemestaneNon-Asian Everolimus + ExemestaneTotal
Complete response (CR)1.5 (0.3 to 4.3)0.00 (NA to NA)1.3 (0.3 to 3.7)
Partial response (PR)20.1 (14.8 to 26.3)8.3 (1.8 to 22.5)18.3 (13.6 to 23.8)
Stable disease (SD)51.3 (44.1 to 58.4)63.9 (46.2 to 79.2)53.2 (46.6 to 59.7)
Progressive disease (PD)18.1 (13.0 to 24.2)19.4 (8.2 to 36.0)18.3 (13.6 to 23.8)
Unknown (UNK)9.0 (5.4 to 13.9)8.3 (1.8 to 22.5)8.9 (5.6 to 13.3)
Overall response rate (ORR: CR+PR)21.6 (16.1 to 28.0)8.3 (1.8 to 22.5)19.6 (14.7 to 25.2)
SecondaryPercentage of Participants Clinical Benefit Rate

Clinical benefit rate: Patients with best overall response rate of CR (any duration), PR (any duration) and SD with duration of 24 weeks or longer according to RECIST 1.1 criteria: Complete Response (CR)=disappearance of target lesions, Partial Response (PR) was \>=30% decrease in sum of diameter of lesions, Progressive Disease (PD) was \>=20% decrease in sum of diameter of lesions, Stable Disease (SD) does not qualify for PR, CR or PD, Unknown=not documented or assessed. Best overall response of CR = at least two determinations of CR at least 4 weeks apart before progression are required. Best overall response of PR = at least two determinations of PR or better at least 4 weeks apart before progression (and not qualifying for a CR) are required. The Overall response rate (ORR) is the percentage of patients with a best overall response of confirmed complete (CR) or partial (PR) response. The 95% confidence intervals (CI) were computed using the Clopper-Pearson method.

Time frame:
Baseline up to approximately 43 weeks for Asian countires and 32 weeks for Non-Asian countries
Reported as:
Number · Percentage of participants
Percentage of Participants Clinical Benefit Rate
Percentage of participantsAsian Everolimus + ExemestaneNon-Asian Everolimus + ExemestaneTotal
Percentage of Participants Clinical Benefit Rate48.2 (41.1 to 55.4)30.6 (16.3 to 48.1)45.5 (39.0 to 52.1)
SecondaryProgression Free Survival (PFS)

PFS is time from date of start of treatment to date of disease progression or death due to any cause, whichever occurs first. b Percentiles with 95% CIs are calculated from PROC LIFETEST output using method of Brookmeyer and Crowley (1982)

Time frame:
Baseline up to approximately 43 weeks for Asian countires and 40 weeks for Non-Asian countries
Reported as:
Median · weeks
Progression Free Survival (PFS)
weeksAsian Everolimus and ExemestaneNon-Asian Everolimus + ExemestaneTotal
Progression Free Survival (PFS)40.6 (39.3 to 50.3)37.0 (26.7 to 52.0)40.6 (38.0 to 48.9)
SecondaryPercent of Participants Event-free Probability Estimates of Deterioration of Eastern Cooperative Oncology Group (ECOG) Performance Status

Time to deterioration of ECOG performance status, from baseline will be assessed using the ECOG Performance Status Scale (Oken, 1982). Time to deterioration is the time from date of start of treatment to the date of the event defined as deterioration. Deterioration is defined as an increase in performance status from 0 to 2 or greater, an increase in performance status from 1-2 to 3 or greater, or death due to any cause. Event-free probability estimate is the estimated probability that a patient will remain event-free up to the specified time point. Event-free probability estimates were are obtained from the Kaplan-Meier survival estimates.

Time frame:
Baseline up to approximately 50 weeks
Reported as:
Number · percent of participants
Percent of Participants Event-free Probability Estimates of Deterioration of Eastern Cooperative Oncology Group (ECOG) Performance Status
percent of participantsAsian Everolimus + ExemestaneNon-Asian Everolimus + ExemestaneTotal
Week 0 n=199,36,235100.0100.0100.00
Week 20 n=134,18,15295.079.892.7
Week 50 n=58,7,6590.670.487.6

Adverse events

Collected over Adverse events were collected from first dose of study treatment until end of study treatment plus 30 days post treatment, up to maximum duration off approximately 43 weeks for Asian countries and 32 weeks for Non-Asian countries. Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Asian6/199 (3%)59/199 (29.6%)192/199 (96.5%)
Non-Asian4/36 (11.1%)16/36 (44.4%)36/36 (100%)
Most frequent serious events
Showing 10 of 85
Most frequent serious events
EventAsianNon-Asian
Abdominal painGastrointestinal disorders0/1993/36
NauseaGastrointestinal disorders0/1993/36
PyrexiaGeneral disorders5/1993/36
Acute kidney injuryRenal and urinary disorders1/1993/36
PneumonitisRespiratory, thoracic and mediastinal disorders4/1993/36
AnaemiaBlood and lymphatic system disorders7/1992/36
StomatitisGastrointestinal disorders1/1992/36
VomitingGastrointestinal disorders0/1992/36
ChillsGeneral disorders0/1992/36
CellulitisInfections and infestations6/1992/36
Most frequent other events
Showing 10 of 174
Most frequent other events
EventAsianNon-Asian
StomatitisGastrointestinal disorders125/19914/36
FatigueGeneral disorders31/19914/36
RashSkin and subcutaneous tissue disorders48/19912/36
Decreased appetiteMetabolism and nutrition disorders53/1999/36
HyperglycaemiaMetabolism and nutrition disorders51/1999/36
Aspartate aminotransferase increasedInvestigations50/1993/36
Mouth ulcerationGastrointestinal disorders7/1999/36
NauseaGastrointestinal disorders23/1999/36
EpistaxisRespiratory, thoracic and mediastinal disorders9/1999/36
Alanine aminotransferase increasedInvestigations45/1994/36

Baseline characteristics

Age, Continuous
Age, Continuous(years)Asian Everolimus + ExemestaneNon-Asian Everolimus + ExemestaneTotal
Mean58.4 ± 10.0060.8 ± 10.2658.8 ± 10.05
Sex/Gender, Customized
Sex/Gender, Customized(Participants)Asian Everolimus + ExemestaneNon-Asian Everolimus + ExemestaneTotal
Females19936235
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Asian Everolimus + ExemestaneNon-Asian Everolimus + ExemestaneTotal
Caucasian72734
Asian1563159
Other36642
08

Study locations

55 sites
  • Novartis Investigative Site
    Garran, Australian Capital Territory 2605, Australia
  • Novartis Investigative Site
    Caringbah, New South Wales 2229, Australia
  • Novartis Investigative Site
    Liverpool, New South Wales 2170, Australia
  • Novartis Investigative Site
    Box Hill, Victoria 3128, Australia
  • Novartis Investigative Site
    Heidelberg, Victoria 3084, Australia
  • Novartis Investigative Site
    Ringwood East, Victoria 3135, Australia
  • Novartis Investigative Site
    St Albans, Victoria 3021, Australia
  • Novartis Investigative Site
    Karamsad, Gujarat 388325, India
  • Novartis Investigative Site
    Nashik, Maharashtra 422 004, India
  • Novartis Investigative Site
    Pune, Maharashtra 411013, India
  • Novartis Investigative Site
    Cuttack, Orissa 753 007, India
  • Novartis Investigative Site
    Bandung, 40161, Indonesia
  • Novartis Investigative Site
    Jakarta, 11420, Indonesia
  • Novartis Investigative Site
    Jogyakarta, 55284, Indonesia
  • Novartis Investigative Site
    Semarang, 50212, Indonesia
  • Novartis Investigative Site
    Amman, 11941, Jordan
  • Novartis Investigative Site
    Suwon, Gyeonggi-do 443380, Korea, Republic of
  • Novartis Investigative Site
    Gyeonggi do, Korea 10408, Korea, Republic of
  • Novartis Investigative Site
    Seoul, Korea 05505, Korea, Republic of
  • Novartis Investigative Site
    Seoul, Seocho Gu 06591, Korea, Republic of
  • Novartis Investigative Site
    Busan, 602739, Korea, Republic of
  • Novartis Investigative Site
    Jeollanam-do, 519763, Korea, Republic of
  • Novartis Investigative Site
    Seoul, 01812, Korea, Republic of
  • Novartis Investigative Site
    Seoul, 02841, Korea, Republic of
  • Novartis Investigative Site
    Seoul, 03080, Korea, Republic of
  • Novartis Investigative Site
    Seoul, 03722, Korea, Republic of
  • Novartis Investigative Site
    Seoul, 06273, Korea, Republic of
  • Novartis Investigative Site
    Seoul, 06351, Korea, Republic of
  • Novartis Investigative Site
    Taegu, 41944, Korea, Republic of
  • Novartis Investigative Site
    Kuala Lumpur, MYS 56000, Malaysia
  • Novartis Investigative Site
    Kota Kinabalu, Sabah 88586, Malaysia
  • Novartis Investigative Site
    Kuala Lumpur, Wilayah Persekutuan 50586, Malaysia
  • Novartis Investigative Site
    Casablanca, Morocco
  • Novartis Investigative Site
    Rabat, 6527, Morocco
  • Novartis Investigative Site
    Cape Town, Western Cape 7925, South Africa
  • Novartis Investigative Site
    George, Western Cape 6530, South Africa
  • Novartis Investigative Site
    Western Cape, 7925, South Africa
  • Novartis Investigative Site
    New Taipei City, TWN 23561, Taiwan
  • Novartis Investigative Site
    Changhua, 50006, Taiwan
  • Novartis Investigative Site
    Kaohsiung City, 83301, Taiwan
  • Novartis Investigative Site
    Kaoshiung, 80756, Taiwan
  • Novartis Investigative Site
    Taipei, 10048, Taiwan
  • Novartis Investigative Site
    Taipei, 10449, Taiwan
  • Novartis Investigative Site
    Bangkok, 10300, Thailand
  • Novartis Investigative Site
    Bangkok, 10400, Thailand
  • Novartis Investigative Site
    Chiang Mai, 50200, Thailand
  • Novartis Investigative Site
    Ariana, 2080, Tunisia
  • Novartis Investigative Site
    Ankara, 06100, Turkey
  • Novartis Investigative Site
    Ankara, 06460, Turkey
  • Novartis Investigative Site
    Ankara, 06500, Turkey
  • Novartis Investigative Site
    Gaziantep, 27310, Turkey
  • Novartis Investigative Site
    Izmir, 35040, Turkey
  • Novartis Investigative Site
    Kartal, 34890, Turkey
  • Novartis Investigative Site
    Pendik / Istanbul, 34899, Turkey
  • Novartis Investigative Site
    Ho Chi Minh, 700000, Vietnam
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2013 to primary completion in Jan 2019, 70 months.

Results were first posted in Apr 2020, 1 year 2 months after primary completion.

Of 272 industry-sponsored phase 3 interventional studies under Breast Neoplasms, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 63. This study's 70 months is above that.

Counting every sponsor, half of 600 studies reached it within 59 months; a quarter within 36 and three quarters within 96.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 1, 2017
First posted
Jun 5, 2017
StartActual
Mar 29, 2013
Primary completionActual
Jan 29, 2019
CompletionActual
Jan 29, 2019
Results first posted
Apr 7, 2020
Last update
Apr 7, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 7, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03176238
Responsible party
Sponsor
First posted
Jun 5, 2017
Start date
Mar 29, 2013
Primary completion
Jan 29, 2019
Completion
Jan 29, 2019
Results posted
Apr 7, 2020
Last update
Apr 7, 2020

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Everolimus

Start the discussion